Chandru P. Sundaram, MD, of Indiana University Department of Urology, and Katie S. Murray, DO, MS, of NYU Langone Urology and Bellevue Hospital, highlight the results of a large multi-institutional study involving robotic nephroureterectomy and bladder cuff excision for upper tract urothelial carcinoma (UTUC). Dr. Sundaram explains the importance of bladder cuff excision in reducing bladder cancer recurrence while also noting the flexibility in treatment for older patients with comorbidities, emphasizing the advantages of robotic surgery in achieving better outcomes. ...
Upper Tract Urothelial Carcinoma
Advertisement
Latest News
Drs. Gupta and Kohlmann focus on the prevalence of pathogenic variants in the urethra, upper tract, and bladder.
Drs. Gupta and Kohlmann discuss why comprehensive germline testing is crucial for accurate diagnosis and treatment of UTUC.
NLR can be a prognostic predictor of clinicopathology in UTUC, aiding risk stratification and management.
A meta-analysis sought to determine the surgical and oncological outcomes of LNU and ONU in patients with UTUC.
For patients with UTUC, bladder cuff excision and radical nephroureterectomy is a longstanding treatment.
The study’s data set included abstracted clinical data with germline and tumor genomic data.
Patients with localized UTUC have high unmet needs and tumors with a high frequency of FGFR3 alterations.
Drs. Packiam and Murray weigh multiple studies exploring gemcitabine/docetaxel as a frontline therapy for UTUC.
Drs. Margulis and Murray showcase the ENLIGHTED study examining the efficacy and safety of padeliporfin VTP for LG UTUC.
Dr. Moussa provides an overview of his research on prognostic factors of relapse in small cell neuroendocrine carcinomas.
Advertisement
Roundtable Discussions
The panel offers concluding thoughts on selection criteria for lymph node dissection in patients with low-grade UTUC.
The panel dissects a longitudinal follow-up of a multicenter study of UGN-101 as well as other 2024 AUA meeting data.
The panel considers how to best treat patients with low-grade UTUC who experience disease recurrence post-surgery.
The panel highlights nephron-sparing approaches as well as current treatment pathways for low-grade UTUC.
The panel provides a disease state overview of low-grade UTUC, including considerations for diagnosis, staging, and grading.
The panel engages in a discussion related to risk stratification in UTUC, including identification of high-risk patients.
Urothelial Cancer Knowledge Hubs
Curated clinical content based on urothelial cancer types, therapies, and technologies
Advertisement
Section Editor
Katie S. Murray, DO, MSUrologic Oncologist | NYU Langone Urology and Bellevue Hospital
Advertisement
Get the latest UTUC research straight to your inbox.
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.